Actively Recruiting

Phase 2
Phase 3
Age: 2Years - 17Years
All Genders
NCT07441876

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Led by BioMarin Pharmaceutical · Updated on 2026-05-07

160

Participants Needed

4

Research Sites

178 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.

CONDITIONS

Official Title

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be aged 2 to less than 11 years (Phase 2) or 2 to less than 18 years (Phase 3) at consent
  • Participants must have achondroplasia confirmed by genetic testing and open growth plates
  • Participants are Tanner Stage I (Phase 2) or any Tanner stage (Phase 3)
  • Participants must be able to walk and stand without assistance
Not Eligible

You will not qualify if you...

  • Participants with any short stature condition other than achondroplasia (e.g., hypochondroplasia, trisomy 21, pseudoachondroplasia, growth hormone deficiency)
  • Participants with untreated thyroid disorders, poorly controlled diabetes, autoimmune or inflammatory diseases, autonomic neuropathy, anemia (hemoglobin below 10 g/dL), vitamin D deficiency, or significant hip problems
  • Participants with a history of kidney or heart disease that increases cardiac risk during low blood pressure
  • Participants with bone fractures in long bones or spine within 6 months before screening
  • Participants who have used vosoritide, other approved or investigational products or devices for achondroplasia or short stature
  • Participants treated with growth hormone, insulin-like growth factor 1, or anabolic steroids within 6 months before treatment start

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Consano Clinical Research, LLC

California City, California, United States, 78231

Actively Recruiting

2

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States, 94609

Actively Recruiting

3

Texas Children Hospital, Baylor College of Medicine, Houston TX

Houston, Texas, United States, 77030

Actively Recruiting

4

Murdoch Children's Research Institute

Parkville, Victoria, Australia, 3052

Actively Recruiting

Loading map...

Research Team

T

Trial Specialist

CONTACT

S

Study Manager

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here